报告题目：CXCR4-targeted, Ultrasmall Nanoclusters as Novel Theranostic Nanoplatform towards Imaging Guided Therapy of Triple-Negative Breast Cancer
报告人：Guorong Sun，Department of Chemistry, Texas A&M University
主持人：张强 研究员
报告时间：2018年7月24日 下午14:00
报告地点：生命科学学院534小会议室
报告人简介：Guorong Sun received his Ph.D. in polymer chemistry in 2009 from Washington University in St Louis (WashU) under the direction of Prof. Karen L. Wooley, working on syntheses and chemoselective modifications of crosslinked polymer nanostructure as imaging and delivery agents. After 6 months of postdoctoral research in Prof. Younan Xia’s research laboratory at WashU, he continued his postdoctoral training with Prof. Wooley at Texas A&M University. Presently he is a Senior Scientist in the Wooley group and leads several collaborative researches on exploring advanced nanomaterials for imaging guided cancer therapy
报告摘要：Beneficial from the advances of controlled polymerization and metal nanoparticle synthesis methodologies, polymer-metal hybrid nanostructures with various compositions, sizes, and morphologies have been achieved, which lead to new diagnostic and therapeutic approaches with improved cancer care outcomes, in terms of accurate diagnosis and personalized treatment. In this regime, ultrasmall polymer-metal nanoclusters (NCs) with hydrodynamic diameter less than 10 nm represent innovative pathway for clinical oncology and cancer research, due to their capacities on enabling reliable renal clearance and enhancing targeted imaging and drug delivery.
This presentation will highlight our recent progress on developments of CXCR4-targeted NCs as novel theranostic nanoplatform towards imaging guided therapy of triple-negative breast cancer (TNBC). The design and synthetic routes to address challenges including achieving low non-specific tumor accumulation to improve detection and delivery specificities, manipulating cluster size and surface coating polymer to realize favorable in vivo biodistribution and pharmacokinetics, introducing full degradability to promote therapeutic agent releasing, and maintaining minimal immunotoxicity to facilitate clinical translation, will be described in detail, along with promising results.